Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine
Status:
Terminated
Trial end date:
2017-07-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the antipruritic efficacy of topical ketamine,
amitriptyline, lidocaine, and a tri-combination of ketamine, amitriptyline and lidocaine
(hereafter referred to as "KeAmLi") using non-histaminergic itch provocations in healthy
volunteers. The primary outcome is itch reduction (AUC) between the vehicle and active
treatment (KeAmLi-combo). Secondary outcomes include modality-specific analgesic properties
of the topically applied ketamine, amitriptyline, lidocaine, and KeAmLi-combo to controlled
quantitative thermal and mechanical stimuli, which can improve our understanding of the
mechanism of action of these substances in the context of topical therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Gil Yosipovitch
Treatments:
Amitriptyline Amitriptyline, perphenazine drug combination Antipruritics Ketamine Lidocaine